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Abstract  An ideal cancer gene therapy would 
selectively destroy the cancer nodules with negligible effects 
on the surrounding not yet compromised tissue. This would 
be possible if the targeted genes are in command positions in 
the cancer but not in the normal cells. Logic dictates that, 
while being strongly protected by the homeostatic 
mechanisms, expression of a commander gene governs most 
major functional pathways by regulating the expression of 
numerous other genes. Owing to the cancer dependence on 
race, sex, age, genetic heritage, medical history, 
environmental and lifestyle associated risk factors each 
patient has most likely a distinct, dynamic and never 
repeatable set of commander genes. Here we introduce the 
“gene commanding height” as a measure of gene rank in the 
cell hierarchy and test our procedure on a surgically removed 
metastatic clear cell renal cell carcinoma. Results indicate 
that each histopathologically distinct region has a unique set 
of commander genes and that cancer cell commanders are in 
low positions in normal cells. We believe that the genomic 
oncology should identify the cancer cell commander genes 
of the individual patient instead of testing for the biomarkers 
selected from most frequently altered genes in large 
populations. 
Keywords  Commander Gene, Gene Commanding 
Height, Gene Networks, Genomic Fabric, Kidney Cancer 
1. Introduction
Most cancers are caused by random changes in the 
genome of individual cells [1, 5]. Tumors are not 
homogeneous but composed of several subpopulations of 
morphologically distinct cell types, pointing to different 
genetic alterations. Cancer development depends on race, 
sex, age, life-style, medical history, and environmental 
exposure to certain toxins and radiations [6]. A very 
important yet not well understood role in cancerization is 
played by the inhabiting microbiota (e.g. [7]) modulated by 
one’s diet. However, most meta-analyses have not 
considered a well-stratified population with respect to all 
combinations of major risk factors. Instead, they collated 
data from several laboratories whose different platforms, 
protocols and data processing procedures question the 
significance (e.g. [8-13]) 
Numerous genomics labs are racing to identify the gene 
whose mutation, epigenetic alteration or/and regulation of 
the expression level indicate with reasonable predictive 
value the occurrence and development of a particular disease 
(e.g. [14, 15]). Such “biomarkers” are selected from the most 
frequently altered genes in meta-analyses of large population 
cohorts. The millions of mutations in the genome of cancer 
cells [16] result in altered sequence and/or abundance of 
mRNA transcribed from thousands of affected genes. 
Although neglected and presumably not with equal effects, 
each of these alterations may contribute to the cancer 
phenotype. Experimental evaluation of the phenotypic 
effects of a particular gene alteration is almost impossible 
given that any gene manipulation affects hundreds of other 
genes as reported in countless studies on genetically 
engineered animals and cell lines (including ours, e.g. [17]). 
Owing to their astronomic number there is no way to 
consider and validate all possible combinations of genes 
whose mutation/regulation might be indicative for a 
particular form of cancer in each population category (e.g. 
there are >17 trillion distinct 10-gene panels selectable from 
100 candidates!). Because of this, no bio-assay can, in 
principle, provide a reasonable predictive value in 
diagnosing a sporadic cancer [18-21]. There are essentially 
innumerable combinations of epigenetic alterations that 
regulate the transcriptome in spite of claims that a particular 
DNA hypermethylation is a pan-cancer marker [22]. 
Nonetheless, each cell should be governed by a set of 
commander genes whose right expression is critical for the 
cell phenotype, survival, proliferation or/and integration in a 
multicellular structure. As such, expression of a commander 
gene should regulate expression of numerous other genes 
while being highly protected by cell homeostasis. The strong 
protection makes a commander gene less alterable by the 
random alterations caused by the stochastic nature of the 
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chemical reactions and therefore not selectable as a disease 
biomarker by the Principal Component Analysis [23]. 
However, when it happens, alteration of a commander gene 
reverberates through the entire cell transcriptome and is 
amplified by the alteration of the genes it commands. If the 
commander genes in cancer cells are commanded in normal 
ones then their smart manipulation might selectively destroy 
the cancer cells from a heterogeneous tumor and may have 
lesser effect on healthy tissue. Because of unique 
combinations of risk factors, the gene chain of command in 
the same type of cancer phenotype is most likely different 
from person to person. 
In previous papers, we defined the genomic fabric [24-28] 
of a given biological process as the transcriptome associated 
with the most interconnected and stably expressed gene 
network responsible for that process. We reported that 
expression level, control and coordination of fabric genes 
depend on tissue, race/strain, sex and sex hormones, age and 
environment etc. and change during development, 
progression of a disease, and in response to various stimuli. 
The Genomic Fabric Paradigm (GFP) switches focus from 
the most frequently altered genes in numerous 
phenotypically similar individuals (biomarkers) to the most 
important genes for the individual patient. 
Using GFP, its advanced analytical tools and a new 
transcriptomic measure “gene commanding height” we here 
propose a procedure to identify the command genes which 
we believe are the most legitimate targets for personalized 
anticancer therapy. 
2. Materials and Methods 
2.1. Strategy 
Our strategy relies on collecting small pieces from 
histopathologically distinct regions of a tumor, split each 
piece in four and profile the transcriptome of each quarter. 
The splits (biological replicas) are like one system tuned to 
slightly different local conditions. The procedure is 
illustrated with a metastatic case of clear cell renal 
carcinoma. 
Profiling four biological replicas provides enough 
accuracy for three independent measures of each gene: i) 
average expression level, ii) expression variability and iii) 
expression coordination with every other gene. Comparing 
the average expression levels of individual genes in a tumor 
cancer sample with respect to the adjacent normal tissue 
identifies the significantly regulated and turned on/off genes 
in that sample. Expression variability among biological 
replicas is an indirect estimate of the control exerted by the 
homeostatic mechanisms to stabilize the abundance of key 
transcripts within narrow interval regardless of 
environmental fluctuations. Most likely the commanded 
genes have the expression levels tied to the commander’s. 
Therefore, the commanded genes are among the 
synergistically and antagonistically expressed partners of the 
commander and can be identified by the significant pair-wise 
Pearson correlation of their expression levels within 
biological replicas. 
2.2. Tumor Samples 
We have profiled the gene expression in frozen specimens 
from a 74y old man with metastatic clear cell renal cell 
carcinoma. The study was part of a project of Dr. DA Iacobas 
approved by New York Medical College’s and Westchester 
Medical Center (WMC) Committees for Protection of 
Human Subjects, commonly known as Institutional Review 
Boards (IRBs) by L-11,376. The approval granted access to 
frozen cancer specimens from the WMC Pathology Archives 
and depersonalized pathology reports, waiving patient’s 
informed consent. 
Four samples were collected from each of NORmal cortex 
and two Primary Tumor regions A and B (PTA, PTB) of the 
right kidney and from a metastatic chest wall lesion (MET). 
PTA and PTB regions were selected based on their gross 
anatomical differences. The samples were small (2 – 8 mm3) 
and chosen to be as homogeneous as possible. However, 
cells of different phenotypes were not completely eliminated 
and expression of their genes might have affected the 
reported results. 
2.3. Microarray 
We used our standard protocol for extraction, reverse 
transcription, fluorescent labeling and hybridization with 
Agilent 4x44k two color gene expression human microarrays 
of total RNA [29]. Raw and processed data complying with 
the Minimum Information About a Microarray Experiments 
(MIAME) have been deposited and are available at [30].  
A gene was listed as differentially expressed between the 
regions α and β if the absolute expression ratio x exceeded 
the unit by twice of the pooled expression variabilities of that 
gene in the two regions (Eq. 1)  
( ) ( )( )2 2( , ) ( ) ( )1 2i i ix CV CVα β α β> + +      (1) 
where CVi(α/β) is the coefficient of variation in the indicated 
region.  
The differential expression was considered as significant 
if the p-value of the heteroscedastic t-test computed with a 
Bonferroni type correction applied to the redundancy group 
of spots probing the same transcript [30] was less than 0.05. 
The method to identify the regulated genes was validated in 
many of our previous transcriptomic studies by comparing 
the microarray results with those obtained by qRT-PCR or 
Western blotting (e.g.: [17, 32, 33]) 
Expression control of a gene in a particular region was 
computed as the complement to 100% of the coefficient of 
variation of the normalized expression levels in the four 
biological replicas profiled in that region. 
 
 Cancer and Oncology Research 5(3): 45-52, 2017 47 
 
Expression coordination of two genes i and j in a region α 
was determined by computing the pair-wise Pearson 
correlation coefficient ρij
α between their corresponding (log2) 
levels in the biological replicas of that region. 
Gene Commanding Height (GCH) score of gene i in 
region α was computed as: 
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where N is the number of all analyzed distinct genes. 
3. Results 
3.1. Clear Cell Renal Cell Carcinoma CCRCC is 
Transcriptomically Heterogeneous 
Figure 1A presents the percentages of differentially 
expressed genes when NORmal, Primary Tumor A, Primary 
Tumor B and METastatic regions (NOR, PTA, PTB and 
MET) were compared to each other. With respect to NOR, 
15.0% of the genes were significantly up- or down-regulated 
in PTA, 11.7% were regulated in PTB and 23.8% in MET. 
Experimental data indicate that MET originated from PTA 
(only 3.6% differentially expressed genes) rather than from 
PTB (23.8% differentially expressed genes). Interestingly, 
more genes were differentially expressed between the two 
primary tumor regions (19.4%) than between each tumor 
region and the reference tissue. The differences between 
PTA and PTB and similarities between PTA and MET are 
evident in Figure 1B, which presents the regulation of cancer 
biomarkers selected from [34]. 
3.2. Cell Proliferation and Spread Increased in CCRCC 
to Counter Up-regulation of the Immune Response 
Phenotypic changes beyond cut-off limits trigger an 
immune attack to kill and eliminate aberrant cells. This is 
consistent with our finding that 19% of the 130 genes 
involved in the chemokine signaling [35] were regulated in 
PTA, 11% in PTB and 18% in MET. These percentages 
indicate also that the immune response was lower in PTB 
than in PTA and MET, concordant with all other findings of 
less severe CCRCC in PTB than PTA. However, although 
attacked by the immune system, cancer cells acquire 
proliferation rates that exceed tissue control mechanisms. 
Indeed, in all three cancer regions we found up-regulation of 
the cyclins CCNB1IP1, CCNC and CCND2 while none of 
the cyclin-dependent kinase inhibitors was affected. 
Cyclin-dependent kinases CDK13, CDK4, CDK5, CDK5R1 
and CDK9 were up-regulated in both PTA and MET but not 
in PTB, perhaps explaining why the faster growing PTA 
cells metastasized to the chest wall. 
 
Figure 1.  (A) Percentages of differentially expressed genes when 
comparing the groups to each-other. Note the significantly lower 
percentage of differentially expressed genes between PTA and MET. (B). 
Regulation of some “known” cancer biomarkers. Red/green/blank square 
indicates whether that gene was significantly up-/down-/not regulated in 
the indicated region with respect to the control tissue. 
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In addition to increased proliferation of cancer cells, 
cancer-inducing molecular factors can spread to neighboring 
cells via gap junction channels. We found that GJA4 gene 
encoding the vascular gap junction protein connexin 37 
(Cx37) was up regulated by 2.1x in PTA, 2.0x in PTB and 
2.4x in MET. GJB2, encoding Cx26, was 2.1x up-regulated 
in PTA, 1.8x down-regulated in PTB and 2.4x up-regulated 
in MET, while GJC1, encoding Cx45, was not regulated in 
PTA and MET but 2.6x down-regulated in PTB. 
Down-regulation of two important connexin genes in PTB 
suggests not only less synchronization of cancer 
development in the neighboring cells but also different 
tumorigenesis mechanisms than in PTA and MET regions. 
3.3. CCRCC Increased the Overall Expression Control 
and Coordination 
The overall expression variability among biological 
replicas was significantly reduced in all CCRCC groups with 
respect to NOR group indicating increased control of 
transcript abundances (Figure 2A). Analysis of expression 
correlation (principle presented in Figure 2B) also revealed 
substantial increases in expression coordination (both 
synergistic and antagonistic) in all CCRCC groups with 
respect to NOR samples (Figure 2C). Note that both 
expression control and expression coordination had smaller 
increases in the region also exhibiting the least expression 
regulation (PTB). 
3.4. CCRCC Rearranged the Gene Networks 
Expression coordination of two genes indicates whether 
they are inter-connected in a gene network. We found that 
all pathways analyzed so far (apoptosis, chemokine 
signaling, mTOR signaling, VEGF signaling, oncogenes 
and mitochondrial genes) as well as their interplays 
exhibited significant network rearrangement. Figure 3 
illustrates the expression inter-coordination for a group of 
20 mitochondrial ATP-synthases. CCRCC not only 
increased the overall expression coordination of these genes, 
but it also modified their partnerships, indicating changes in 
mitochondrial function. For instance, ATP6 
(mitochondrially encoded ATP synthase 6) has no 
significant coordination partner in NOR but it is 
independently expressed with ATP5G2. However, it has 4 
synergistically expressed partners in PTA including 
ATP5G2, 1 in PTB and 11 in MET. 
 
Figure 2.  CCRCC increases expression control and coordination. (A). Average control of gene expression level among biological replicas of the four 
regions. The overall reduction of the coefficient of variation (CV) was evident for all genes as well as for the separately analyzed pathways. Note that CV 
reduction was smaller for PTB samples than for PTA and MET ones. (B). Examples of genes that are synergistically (KDR = kinase insert domain receptor 
(a type III receptor tyrosine kinase)), antagonistically (CDC42 = cell division cycle 42) and independently (MAPKAPK2 = mitogen-activated protein 
kinase-activated protein kinase 2) expressed with VEGFA (transcript variant 1) in PTB. Numbers above linear regression lines are the Pearson pair-wise 
correlation coefficients between the sets of (log2) expression levels within biological replicas of the correlated genes. (C). Coordination percentages when all 
genes are considered and when the analysis is restricted to separately analyzed groups of genes/pathways. Note the increase of coordination percentage in 
cancer samples. Observe also that the mitochondrial genes were the most affected. 
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Figure 3.  Expression coordination among 20 mitochondrial ATP-synthases in the four profiled regions. A red/blue/(dashed) black line indicates that 
the linked genes are (p < 0.05) synergistically, antagonistically or independently expressed, while a missing line means lack of statistical evidence to 
characterize the coordination. Percentages of coordination for these genes were respectively: 64% (NOR), 82% (PTA), 70% (PTB) and 78% (MET). Note 
the increase of coordination in cancer samples and the changes in expression pairing. Gene symbol in a square box (e.g., ATP5L2) indicates significant 
up-regulation in that region with respect to the normal kidney tissue. 
 
Figure 4.  Gene Commanding Height. (A) GCH of several “known” cancer biomarkers, oncogenes, mitochondrial genes (MIT) and genes involved in 
apoptosis and chemokine signaling (CHE). Color arrows indicate the command genes in each region. (B) Relative GCH of selected command genes in 
regions other than they command. 
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3.5. Histopathologically Distinct Regions have Different 
Command Genes 
We defined (Eq.2) the Gene Commanding Height (GCH) 
in a particular region as a composite score accounting for 
gene expression stability and pooled expression coordination 
with expressions of other genes within biological replicas of 
that region. GCH replaces our Gene Prominence Score 
[24-27] used to select the most important pathway genes. 
Figure 4A presents the commanding heights of several 
“known” cancer biomarkers, oncogenes, mitochondrial 
genes (MIT) and genes involved in apoptosis and chemokine 
signaling (CHE). Results show that the four regions have 
different gene hierarchies. Interestingly, the mitochondrial 
GTPBP3 (GTP binding protein 3) tops both PTA (GCH = 79) 
and PTB (GPS = 95), while PMPCA (peptidase 
(mitochondrial processing) alpha, GPS = 74) tops the normal 
tissue. Genes in MET were less clearly differentiated, the top 
gene, GNAQ (guanine nucleotide binding protein (G protein), 
q polypeptide) GPS = 33, being much less prominent than the 
command genes in other regions. Interestingly, GNAQ was 
the single biomarkers that exhibited a higher GCH in a 
cancer region. 
Importantly, the commanding genes in one region can be 
commanded in other regions. Thus, manipulation of such a 
gene is expected to have profoundly different effects on 
histopathologically distinct regions of the tumor. Figure 4B 
presents the percentage from the maximum commanding 
heights of some command genes in other regions than they 
command. For this particular patient, GTPBP3 is 15x more 
powerful in PTA, 18x in PTB and 5x in MET cells than in 
NOR. In contrast, PMPCA is 6x less powerful in PTA, 11x in 
PTB and 9x in MET than in NOR region. Therefore, the most 
legitimate gene to target for this patient is GTPBP3. 
4. Discussion 
This study does not propose new universal biomarkers for 
a particular form of cancer in ALL humans. Since any cancer 
phenotype is the result of all gene alterations (albeit with 
uneven contributions), and that the number of possible 
combinations of gene alterations is practically infinite, we 
will never be able to determine the predictive value of all 
combinations in the meta-analysis of a really stratified 
population. Besides, the biomarkers are selected from the 
most frequently altered genes in cancer patients (indicating 
less effort of cell homeostasis to protect their 
sequence/expression as for low plyers) and therefore 
targeting them may not bring much therapeutic benefits. 
Instead, we propose a personalized procedure to identify for 
EACH patient the genes whose manipulation might have the 
largest impact on cancer cells because of their regulating the 
expression of numerous other genes while being highly 
protected by homeostatic mechanisms. 
We chose the transcriptomic features because in the end 
almost all kind of mutations affects the transcription level of 
the affected gene. GFP characterizes the organizational 
principles [36] of the (here) kidney cortex transcriptome for 
each individual aiming to determine the critical limits of their 
alteration beyond which there is a spontaneous progression 
to CCRCC. GFP can use transcriptomic data obtained with 
any high throughput gene expression platform when at least 
four biological replicas are profiled from each condition. 
The 4-replicas design provides adequate accuracy for the 
expression variability and expression control, two additional 
independent measures complementing the average 
expression level. 
The expression variability can be used to estimate the 
strength of the homeostatic control of transcript abundance 
[35]. We have speculated that expression of genes that are 
critical for cell survival, differentiation and integration in a 
multicellular structure should be under a stricter control. 
Thus, identification of the most controlled genes in a 
particular condition will indicate the cell “priorities” in that 
condition. Until a point of no return, the cell is expected to 
increase the overall control of transcript abundances to 
attenuate/limit the damaging effects of a disease or an 
environmental stress. However, cells should have genes 
whose relaxed control allows easy adaptation to 
environmental fluctuations in each condition and for each 
functional pathway. Interestingly, in many other microarray 
studies [31, 33, 37-40] we observed an overall reduction of 
expression variability (indicating increased) control in 
tissues from diseased, genetically manipulated or stressed 
animals compared to their healthy counterparts. In this study, 
we found an overall increase of the expression control in all 
cancer regions, the smallest increase being observed in the 
region (PTB) having also a smaller number of regulated 
genes. Therefore, we believe that increase of the expression 
control can be a universal criterion to assess the cancer stage. 
The expression correlation indicates what genes can be 
included in functional pathways as satisfying a kind of 
“transcriptomic stoichiometry” [38]. When two genes are 
synergistically expressed the synthesis rates of the encoded 
proteins oscillate in synchrony while these rates manifest 
opposite tendencies when the genes are antagonistically 
expressed. Expression synergism and antagonism are 
essential for the performance of functional pathways. We 
consider the synergistically and antagonistically expressed 
genes as interconnected in transcriptomic networks. 
Transcriptomic networks may cross cell borders via 
intercellular communication. Thus, regulation of certain 
genes in one cell has consequences on the expression level of 
other genes in neighboring cells, even when neighbors are of 
different types [26, 41]. 
If two genes are independently expressed then there is 
little chance that their encoded proteins are part of the same 
functional pathway. In this study, we found an overall 
increase of expression coordination in all cancer regions. 
And, again, the smallest increase was in the least affected 
region (PTB). We have also reported increase of expression 
coordination in previous microarray studies on mice 
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subjected to chronic intermittent or constant hypoxia [40]. 
Therefore, we believe that increases in expression 
coordination can be also a universal criterion to assess the 
stage of a cancer. 
While biomarkers are selected by the Principal 
Component Analysis [23] as the most informative subset of 
genes for the transcriptomic alterations, GFP uses the 
Prominence Gene Analysis [24-26] and the Gene 
Commanding Height [28] to establish the gene chain of 
command in each condition. Top commander genes are 
under stricter protection of the homeostatic mechanisms (and 
by consequence among the least alterable) while 
coordinating expression of most other genes of the pathway. 
This study verified that in a heterogeneous tumor each 
histopathologically distinct region has a different set of 
commander genes. If a commander gene in cancer cells (like 
GTPBP3 here) has significantly lower GCH in normal tissue, 
then it could be a potential target to push cell physiological 
parameters beyond viable levels in cancer cells leading to 
selective destruction whilst preserving function/survival of 
cells in normal tissue. 
It is possible that certain candidate genes have already 
FDA approved targeting therapies. Thus, our procedure 
could be a firm step towards a really personalized genomic 
cancer medicine.  
In order to test the usefulness of our procedure we should 
overexpress the commanders that stimulate cancer cell death 
and/or tumor suppression or silence the commanders 
involved in proliferation and/or spreading. Unfortunately, we 
had no possibility to validate for this patient what 
manipulation of command genes can do. However, 
experiments on several mouse and human cancer cell lines 
are underway to test whether manipulation of command 
genes affects selectively the cells they command. Further 
studies on various cancer types are also necessary to test the 
usefulness of the overall expression control and expression 
coordination for cancer transcriptomic grading. 
5. Conclusions 
Instead of using standard gene panels with disputable 
predictive value for the current patient, we would likely 
profile the cancer nodules, identify the commander genes 
and target them. 
Acknowledgements 
Surgery was performed by Dr. R.J. Lafaro at Westchester 
Medical Center and the pathology report was written by Dr. 
M Zhong. Drs. Randy F. Stout (NYIT), Henry P. Godfrey 
(NYMC) and David C Spray (Einstein) are acknowledged 
for their valuable critical comments on the manuscript. 
Funding: NYMC Department of Pathology 
Author Contributions: SI conducted the microarray 
experiment and DAI developed the method, design the 
experiment and performed the analyses. Both authors 
contributed to the manuscript writing. 
Competing Interests: no competing interests. 
 
REFERENCES 
[1] http://www.cancer.gov 
[2] http://cancergenome.nih.gov 
[3] https://tcga-data.nci.nih.gov/tcga 
[4] Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic 
mutations, cancer etiology, and cancer prevention. Science. 
24;355(6331):1330-1334, 2017 
[5] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz 
LA Jr, Kinzler KW. Cancer genome landscapes. Science. 
339(6127):1546-58.5, 2013. 
[6] http://www.cancer.ca/en/cancer-information/cancer-101/what
-is-a-risk-factor/genetic-risk/sporadic-mutations/?region=on 
[7] Bultman SJ. The microbiome and its potential as a cancer 
preventive intervention. Semin Oncol. 43(1):97-106, 2016. 
[8] Bagrodia A, Cha EK, Sfakianos JP, Zabor EC, Bochner BH, 
Al-Ahmadie HA, Solit DB, Coleman JA; Collaborators (11). 
Genomic biomarkers for the prediction of stage and prognosis 
of upper tract urothelial carcinoma. J Urol. pii: 
S0022-5347(16)00033-1, 2016. 
[9] Chen J, Gong TT, Wu QJ. Parity and gastric cancer risk: a 
systematic review and dose-response meta-analysis of 
prospective cohort studies. Sci Rep. 6:18766, 2016. 
[10] Karim S. Assessment of radiation induced therapeutic effect 
and cytotoxicity in cancer patients based on transcriptomic 
profiling. Int. J Mol Sci. 17(2). pii: E250, 2016. 
[11] Nq KL , Morais C, Bernard A, Saunders N, Samaratunga H, 
Gobe G, Wood S. A systematic review and meta-analysis of 
immunohistochemical biomarkers that differentiate 
chromophobe renal cell carcinoma from renal oncocytoma. J 
Clin Pathol. pii: jclinpath-2015-203585, 2016. 
[12] Schubert M, Junker K, Heinzelmann J. Prognostic and 
predictive miRNA biomarkers in bladder, kidney and prostate 
cancer: Where do we stand in biomarker development? J 
Cancer Res Clin Oncol. 142(8):1673-95, 2016. 
[13] Yao J , Li ZH, Li YX, Zhang R, Zhang DG, Xu ZL, Wang LS, 
Wang JY. Association between the -607 C > A polymorphism 
in interleukin-18 gene promoter with gastrointestinal cancer 
risk: a meta-analysis. Genet Mol Res. 14(4):16880-7, 2015. 
[14] Lucarelli G, Rutigliano M, Sanguedolce F, Galleggiante V, 
Giglio A, Cagiano S, Bufo P, Maiorano E, Ribatti D, Ranieri E, 
Gigante M, Gesualdo L, Ferro M, de Cobelli O, Buonerba C, 
Di Lorenzo G, De Placido S, Palazzo S, Bettocchi C, Ditonno 
P, Battaglia M. Increased Expression of the Autocrine Motility 
Factor is Associated With Poor Prognosis in Patients With 
Clear Cell-Renal Cell Carcinoma. Medicine (Baltimore) 
94(46):e2117, 2015. 
[15] Mo R, Peng J, Xiao J, Ma J, Li W, Wang J, Ruan Y, Ma S, 
Hong Y, Wang C, Gao K, Fan J. High TXNDC5 expression 
 
52 Towards a Personalized Cancer Gene Therapy: A Case of Clear Cell Renal Cell Carcinoma  
 
predicts poor prognosis in renal cell carcinoma. Tumor Biol. 
37(7):9797-806, 2016. 
[16] Kohane IS, Hsing M, Kong SW. Taxonomizing, sizing, and 
overcoming the incidentalome. Genet Med 14, 399-404, 2012. 
[17] Iacobas DA, Iacobas S, Urban-Maldonado M, Scemes E, 
Spray DC. Similar transcriptomic alterations in Cx43 
knock-down and knock-out astrocytes. Cell Commun. Adhes 
15, 195-206, 2008. 
[18] Amaro A, Esposito AI, Gallina A, Nees M, Angelini G, Albini 
A, Pfeffer U. Validation of proposed prostate cancer 
biomarkers with gene expression data: a long road to travel. 
Cancer Metastasis Rev. 33(2-3):657-71. Review, 2014. 
[19] Klein EA , Cooperberg MR, Magi-Galluzzi C, Simko JP, 
Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis 
AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner 
FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, 
Carroll PR. A 17-gene assay to predict prostate cancer 
aggressiveness in the context of Gleason grade heterogeneity, 
tumor multifocality, and biopsy undersampling. Europ. Urol 
66, 550-560, 2014. 
[20] Luo Y, Zhu X, Zhang P, Shen Q, Wang Z, Wen X, Wang L, 
Gao J, Dong J, Yang C, Wu T, Zhu Z, Tian Y. The clinical 
performance evaluation of novel protein chips for eleven 
biomarkers detection and the diagnostic model study. Int J 
Clin Exp Med. 8(11):20413-23, 2015.  
[21] Wu CL, Schroeder BE, Ma XJ, Cutie CJ, Wu S, Salunga R, 
Zhang Y, Kattan MW, Schnabel CA, Erlander MG, McDougal 
WS. Development and validation of a 32-gene prognostic 
index for prostate cancer progression. PNAS 110 (15): 6121-6, 
2013.  
[22] Margolin G, Petrykowska HM, Jameel N, Bell DW, Young 
AC, Elnitski L. Robust detection of DNA hypermethylation of 
ZNF154 as a pan-cancer locus with in silico modeling for 
blood-based diagnostic development. J Mol Diagn. 
18(2):283-98, 2016. 
[23] Draghici S. Data analysis tools for DNA microarrays, 
Chapman & Hall, Boca Raton, pp. 223-224, 2003. 
[24] Iacobas DA, Iacobas S, Haddad GG. Heart rhythm genomic 
fabric in hypoxia. Biochem. Biophys. Res. Commun. 
391(4):1769-1774, 2010.  
[25] Iacobas DA, Iacobas S, Thomas N, Spray DC. Sex-dependent 
gene regulatory networks of the heart rhythm. Funct Integr 
Genomics. 10(1):73-86, 2010. 
[26] Iacobas S, Iacobas DA. Astrocyte proximity modulates the 
myelination gene fabric of oligodendrocytes. Neuron Glia 
Biology 6(3): 157-169, 2010. 
[27] Iacobas DA, Iacobas S, Chachua T, Goletiani C, Sidyelyeva G, 
Velíšková J, Velíšek L. Prenatal corticosteroids modify 
glutamatergic and GABAergic synapse genomic fabric: 
Insights from a novel animal model of infantile spasms. J 
Neuroendocrinol. 25, 964-979, 2013.  
[28] Iacobas DA. The Genomic Fabric Perspective on the 
Transcriptome between Universal Quantifiers and 
Personalized Genomic Medicine. Biological Theory. 11(3): 
123-137, 2016. 
[29] Lee PR, Cohen JE, Iacobas DA, Iacobas S, Fields RD. 
Gene-regulatory networks activated by pattern-specific 
generation of action potentials in dorsal root ganglia neurons. 
Scientific Reports. 7:43765, 2017. 
[30] http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE723
04 
[31] Iacobas DA, Iacobas S, Urban-Maldonado M, Spray DC. 
Sensitivity of the brain transcriptome to connexin ablation, 
Biochimica et Biofisica Acta. 1711: 183-196, 2005. Review./ 
[32] Fan C, Iacobas DA, Zhou D, Chen Q, Gavrialov O, Haddad 
GG. Gene expression and phenotypic characterization of 
mouse heart after chronic constant and intermittent hypoxia. 
Physiol Genomics. 22: 292-307, 2005. 
[33] Iacobas DA, Iacobas S, Li WE, Zoidl G, Dermietzel R, Spray 
DC. Genes controlling multiple functional pathways are 
transcriptionally regulated in connexin43 null mouse heart. 
Physiol Genomics 20: 211-223, 2005. 
[34] http://www.illumina.com/products/truseq_amplicon_cancer_
panel.html 
[35] http://www.genome.jp/kegg-bin/show_pathway?hsa04062 
[36] Spray DC, Iacobas DA. Organizational principles of the 
connexin-related brain transcriptome. J Membr Biol. 
218(1-3):39-47, 2007. 
[37] Iacobas DA, Fan C, Iacobas S, Spray DC, Haddad GG. 
Transcriptomic changes in developing kidney exposed to 
chronic hypoxia. Biochem Biophys Res Comm. 349(1), 
329-338, 2006. 
[38] Iacobas DA, Iacobas S, Spray DC Connexin43 and the brain 
transcriptome of the newborn mice. Genomics. 89(1), 113-123, 
2007. 
[39] Iacobas DA, Iacobas S, Spray DC. Connexin-dependent 
transcellular transcriptomic networks in mouse brain. Prog 
Biophys Mol Biol. 94(1-2):168-184, 2007. Review. 
[40] Iacobas S, Iacobas DA. Effects of Chronic Intermittent 
Hypoxia on Cardiac Rhythm Transcriptomic Networks. In: 
Intermittent Hypoxia and Human Diseases, (Editors: L. XI, 
T.V. Serebrovskaya), New York: Springer. Pp. 15-28, 2012.  
[41] Iacobas S, Thomas NM, Iacobas DA. Plasticity of the 
myelination genomic fabric. Mol Gen Genom. 287, 237-246, 
2012.
 
 
